Mutations of LKB1 frequently co-occur with KRAS and TP53 mutations in NSCLC, which are associated with a higher risk of metastasis and poor prognosis compared with KRAS or TP53 mutation alone [83, 84]. Here, KRAS is linked to non-small cell lung carcinoma.